Computational validation of the importance of absolute stereochemistry in virtual screening

Journal of Chemical Information and Modeling

Volumn 48, Issue 3, 2008, Pages 639-645

  Brooks, Wesley H ^a   Daniel, Kenyon G ^a   Sung, Shen Shu ^a   Guida, Wayne C ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIRALITY; DOCKING; ENANTIOMERS; STEREOCHEMISTRY;

DRUG DISCOVERY; THERAPEUTIC EFFECT;

PROTEINS;

ARTICLE; CHEMICAL STRUCTURE; DRUG SCREENING; STEREOISOMERISM; VALIDATION STUDY;

DRUG EVALUATION, PRECLINICAL; MODELS, MOLECULAR; STEREOISOMERISM;

EID: 42149115851     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci700358r     Document Type: Article

References (26)

1. Caldwell, J. The importance of stereochemistry in drug action and disposition. J. Clin. Pharmacol. 1992, 32, 925-9.
2. Ariens, E. J. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol. 1984, 26, 663-8.
3. Hurt, A. J.; O'Grady, J. Drug chirality: a consideration of the significance of the stereochemistry of antimicrobial agents. J. Antimicrob. Chemother. 1996, 37, 7-32.
4. Garrett, R. H.; Grisham, C. M. Biochemistry, 3rd ed.; Thompson Brooks/Cole: Belmont, 2005; p 1086.
5. Beroza, P.; Suto, M. J. Designing chiral libraries for drug discovery. Drug Discovery Today 2000, 5, 364-372.
6. Thayer, A. M. Centering on Chirality. Chem. Eng. News 2007, 11-19.
7. FDA. FDA's policy statement for the development of new stereoisomeric drugs. http://www.fda.gov/cder/guidance/stereo.htm (accessed Nov 20, 2007).
8. Thayer, A. M. Trial Separations. Chem Eng. News 2005, 49.
9. Thayer, A. M. Chiral Catalysis. Chem Eng. News 2005, 83, 40.
10. Ghosh, S.; Nie, A.; An, J.; Huang, Z. Structure-based virtual screening of chemical libraries for drug discovery. Curr. Opin. Chem, Biol. 2006, 10, 194-202.
11. NCI. Developmental Therapeutics Program, http://dtp.nci.nih.gov/ (accessed Nov 20, 2007).
12. Sadowski, J.; Gasteiger, J.; Klebe, G. Comparison of Automatic Three-Dimensional Model Builders Using 639 X-Ray Structures. J. Chem. Inf. Comput. Sci. 1994, 1000-1008.
13. Pearlman, R. Rapid Generation of High Quality Approximate 3-dimension Molecular Structures. Chem. Des. Auto News 1987, 2.
14. MDL/ISIS Draw; MDL Information Systems Inc.: San Leandro, CA, 2002
15. Xiao, Z. X.; Chen, J.; Levine, A. J.; Modjtahedi, N.; Xing, J.; Sellers, W. R.; Livingston, D. M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995, 375, 694-8.
16. Martin, K.; Trouche, D.; Hagemeier, C.; Sorensen, T. S.; La Thangue, N. B.; Kouzarides, T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995, 375, 691-4.
17. Zheleva, D. I.; Mclnnes, C.; Baxter, C.; Gibson, D.; Maccallum, D.; Powers, H.; Duncan, K.; Bailey, K.; Cummings, L.; Thomas, M.; Wang, S.; Turner, N.; Uhrinova, S.; Barlow, P.; Taylor, P.; Walkinshaw, M.; Lane, D.; Fischer, P. Bisarylsulfonamides - novel small molecule inhibitors of p53-Mdm2 interactioa Proc. Am. Assoc. Cancer Res. 2004, 5552.
18. Lu, Y.; Nikolovska-Coleska, Z.; Fang, X.; Gao, W.; Shangary, S.; Qiu, S.; Qin, D.; Wang, S. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. J. Med. Chem. 2006, 49, 3759-62.
19. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274, 948-53.
20. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N. and Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-42.
21. Klein, C.; Vassilev, L. T. Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer 2004, 91, 1415-9.
22. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303, 844-8.
23. Schrödinger Soflwawre Suite; Schrodinger LLC: New York, 2006.
24. Guex, N.; Peitsch, M. C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997, 18, 2714-23.
25. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific LLC: Palo Alto, CA, 2002.
26. Shoichet, B. K. DUD - A Directory of Useful Decoys, http://dud.docking.org/ (accessed Nov 20, 2007).